Search results for "interleukin"

showing 10 items of 1856 documents

Epithelial NEMO links innate immunity to chronic intestinal inflammation

2007

Deregulation of intestinal immune responses seems to have a principal function in the pathogenesis of inflammatory bowel disease(1-4). The gut epithelium is critically involved in the maintenance of intestinal immune homeostasis-acting as a physical barrier separating luminal bacteria and immune cells, and also expressing antimicrobial peptides(3,5,6). However, the molecular mechanisms that control this function of gut epithelial cells are poorly understood. Here we show that the transcription factor NF kappa B, a master regulator of pro-inflammatory responses(7,8), functions in gut epithelial cells to control epithelial integrity and the interaction between the mucosal immune system and gu…

ColonAntimicrobial peptidesApoptosisBiologyPathogenesisInterleukin 22MiceImmune systemAnimalsHomeostasisMultidisciplinaryInnate immune systemNF-kappa BEpithelial CellsColitisImmunity InnateI-kappa B KinaseGut EpitheliumCell biologyIntestinesReceptors Tumor Necrosis Factor Type IChronic DiseaseMyeloid Differentiation Factor 88Tumor Necrosis FactorsImmunologyChronic inflammatory responseTumor necrosis factor alphaSignal TransductionNature
researchProduct

Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies …

1996

There is now increasing evidence that hyperresponsiveness towards intestinal flora is a crucial event in the pathogenesis of inflammatory bowel disease (IBD). In support of this hypothesis, we recently described in humans that tolerance exists towards indigenous intestinal flora but is broken in active IBD lesions. In the present study, we have attempted to transfer this model into mice from different genetic backgrounds (BALB/c, SJL/J, C3H/HeJ). We found that mononuclear cells from spleen, small bowel and large bowel of mice do not proliferate, i.e. are tolerant when exposed to bacterial sonicates derived from autologous intestine (BsA) but do proliferate, i.e. are immune when exposed to b…

ColonImmunologySpleenBiologyLymphocyte ActivationInflammatory bowel diseaseMicrobiologyMicePeyer's PatchesImmune systemCrohn DiseaseSpecies SpecificityImmunityIntestine SmallImmune TolerancemedicineAnimalsHumansImmunologic FactorsImmunology and AllergyColitisMice Inbred BALB CMice Inbred C3HBacteriaAntibodies MonoclonalInterleukinColitismedicine.diseaseInterleukin-12Recombinant ProteinsInterleukin-10RatsSpecific Pathogen-Free OrganismsIntestinesDisease Models AnimalInterleukin 10medicine.anatomical_structureTrinitrobenzenesulfonic AcidImmunologyLeukocytes MononuclearInterleukin 12SpleenEuropean Journal of Immunology
researchProduct

Cytokines in Colitis-Associated Cancer: Potential Drug Targets?

2008

In inflammatory bowel disease (IBD), such as UC and CD, the development of colorectal carcinoma can be initiated through chronic inflammation, depending on the duration and severity of the disease. Growing evidence supports a role for various cytokines, released by epithelial and immune cells, in the pathogenesis of colitis associated cancer (CAC). For instance, TNF-alpha has been recently shown to promote tumor development in experimental colitis. Due to its role in the pathogenesis of IBD, TNF-alpha blockade has become one of the cornerstones of IBD therapy. Thus, anti-TNF-alpha strategies could also provide effective anti-tumor therapies. TGF-beta has been shown to attenuate an anti-tumo…

Colorectal cancerImmunologyInflammationInflammatory bowel diseasePathogenesisImmune systemT-Lymphocyte SubsetsAnimalsHumansImmunology and AllergyMedicineColitisPharmacologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryCancerGeneral MedicineColitisInflammatory Bowel Diseasesmedicine.diseaseInterleukin-12Interleukin-10ImmunologyCytokinesTumor necrosis factor alphamedicine.symptomColorectal NeoplasmsbusinessInflammation & Allergy - Drug Targets
researchProduct

Mucosal immunology and probiotics.

2013

The cross-talk between the mucosa-associated immune system and microbiota is critical in mucosal tissue homeostasis as well as in protection against infectious and inflammatory diseases occurring at mucosal sites. This recent evidence has paved the way to therapeutic approaches aimed at modulating the mucosa-associated immune system using probiotics. Different strains of probiotics possess the ability to finely regulate dendritic cell (DC) activation, polarizing the subsequent T cell activity toward Th1 (e.g. Lactobacillus (Lb) acidophilus), Th2 (Lb.reuteri and Bifidobacterium bifidum) or, as more recently demonstrated, Th17 responses induced by specific strains such as Lb.rhamnosus GG and …

Commensal bacteriaSettore MED/07 - Microbiologia E Microbiologia ClinicaAllergyPRRT- cell polarizationved/biology.organism_classification_rank.speciesAutoimmunityProbioticInflammatory bowel diseaseMALTTh1Th2Immunology and AllergyIECBifidobacteriumbiologyMicrobiotaImmune-mediated diseasefood and beveragesPAMPCrohn's diseasemedicine.anatomical_structureMucosal immunologyImmunotherapyTh17HumanPulmonary and Respiratory MedicineSettore MED/17 - Malattie InfettiveT cellImmunologyImmunopathologyDendritic CellMicrobiologyImmune systemBifidobacteriaImmunityTLRmedicineGALTAnimalsHumansImmunity MucosalLABLactobacilluInnate immune systemBifidobacterium bifidumUlcerative colitiMucous Membraneved/biologyAnimalProbioticsDendritic cellDendritic CellsInterleukinbiology.organism_classificationImmunity InnateLactobacillusMucosal immunologyLactobacilliImmune SystemImmunologyBifidobacteriumCurrent allergy and asthma reports
researchProduct

Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in…

2021

Abstract Background There is mounting evidence on the existence of a Pediatric Inflammatory Multisystem Syndrome-temporally associated to SARS-CoV-2 infection (PIMS-TS), sharing similarities with Kawasaki Disease (KD). The main outcome of the study were to better characterize the clinical features and the treatment response of PIMS-TS and to explore its relationship with KD determining whether KD and PIMS are two distinct entities. Methods The Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients diagnosed with KD (Kawasaki Disease Group – KDG) or KD-like (Kawacovid Group - KCG) disease between February 1st 2020, and May 31st 2020. Demographic, clini…

Coronary artery abnormalities; Hypotension; Kawasaki disease; Multisystem inflammatory syndrome associated with coronavirus disease; Myocarditis; Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; COVID-19; Child; Child Preschool; Coronary Artery Disease; Cough; Diarrhea; Dyspnea; Female; Glucocorticoids; Heart Failure; Humans; Hyperferritinemia; Hypotension; Immunoglobulins Intravenous; Immunologic Factors; Infant; Intensive Care Units Pediatric; Interleukin 1 Receptor Antagonist Protein; Italy; Lymphopenia; Male; Mucocutaneous Lymph Node Syndrome; Myocarditis; Platelet Aggregation Inhibitors; SARS-CoV-2; Shock; Systemic Inflammatory Response Syndrome; Tachypnea; Troponin T; VomitingMalelcsh:Diseases of the musculoskeletal systemcoronary artery abnormalities; hypotension; kawasaki disease; multisystem inflammatory syndrome associated with coronavirus disease; myocarditis; pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; age distribution; antirheumatic agents; aspirin; C-reactive protein; COVID-19; child ; preschool; coronary artery disease; cough; diarrhea; yspnea; female; glucocorticoids; heart failure; humans; hyperferritinemia; hypotension; immunoglobulins; intravenous; immunologic factors; infant; intensive care units; pediatric; interleukin 1 receptor antagonist protein; italy; lymphopenia; male; mucocutaneous lymph node syndrome; myocarditis; platelet aggregation inhibitors; SARS-CoV-2; shock; systemic inflammatory response syndrome; tachypnea; troponin T; vomitingMyocarditiCoronary Artery Disease030204 cardiovascular system & hematologySARS-CoV-2 Kawasaki disease Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection Myocarditis Hypotension Multisystem inflammatory syndrome associated with coronavirus disease Coronary artery abnormalitiesCoronary artery diseaseSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineGlucocorticoidImmunologic FactorMultisystem inflammatory syndrome associated with coronavirus diseaseImmunology and AllergyChildCoronary artery abnormalitieFisher's exact testPediatricTachypneabiologylcsh:RJ1-570Antirheumatic AgentImmunoglobulins IntravenousShockPediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infectionSettore MED/38Systemic Inflammatory Response SyndromeIntensive Care UnitsMyocarditisC-Reactive ProteinItalyAntirheumatic AgentsChild PreschoolCohortsymbolsPlatelet aggregation inhibitorFemaleHypotensionIntravenousCoronary artery abnormalitiesHumanResearch ArticleDiarrheamedicine.medical_specialtyMyocarditisVomitingImmunoglobulinsMucocutaneous Lymph Node SyndromeIntensive Care Units Pediatric03 medical and health sciencessymbols.namesakeAge DistributionRheumatologyTroponin TInternal medicineLymphopeniamedicineHumansImmunologic FactorsPreschoolGlucocorticoids030203 arthritis & rheumatologyHeart FailureAspirinKawasaki diseasebusiness.industrySARS-CoV-2Platelet Aggregation InhibitorC-reactive proteinCOVID-19Infantlcsh:Pediatricsmedicine.diseaseSystemic inflammatory response syndromeInterleukin 1 Receptor Antagonist ProteinDyspneaCoughImmunoglobulins IntravenouPediatrics Perinatology and Child Healthbiology.proteinKawasaki diseaseHyperferritinemialcsh:RC925-935businessPlatelet Aggregation InhibitorsPediatric rheumatology online journal
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

Toll-like receptors are part of the innate immune defense system of sponges (demospongiae: Porifera).

2006

During evolution and with the emergence of multicellular animals, the need arose to ward off foreign organisms that threaten the integrity of the animal body. Among many different receptors that participate in the recognition of microbial invaders, toll-like receptors (TLRs) play an essential role in mediating the innate immune response. After binding distinct microbial components, TLRs activate intracellular signaling cascades that result in an induced expression of diverse antimicrobial molecules. Because sponges (phylum Porifera) are filter feeders, they are abundantly exposed to microorganisms that represent a potential threat. Here, we describe the identification, cloning, and deduced …

CroatiaMolecular Sequence Datachemistry.chemical_compoundGeneticsAnimalsCluster AnalysisAmino Acid SequenceReceptorMolecular BiologyEcology Evolution Behavior and SystematicsIn Situ HybridizationPhylogenyDeath domainDNA PrimersToll-like receptorInnate immune systembiologyBase SequenceEffectorToll-Like ReceptorsLipopeptideSequence Analysis DNAbiology.organism_classificationBlotting NorthernImmunohistochemistryImmunity InnateCell biologyPoriferaSuberites domunculaInterleukin-1 Receptor-Associated KinaseschemistryCaspasesImmunologySignal transductionMolecular biology and evolution
researchProduct

P008 Differences in macrophage infiltration and Wnt ligands expression between stricturing and penetrating behaviour in Crohn’s disease

2018

Crohn's diseaseFrizzledbiologybusiness.industryColorectal cancermedicine.medical_treatmentGastroenterologyWnt signaling pathwayInterleukinGeneral Medicinemedicine.diseaseCytokineFibrosisCancer researchbiology.proteinMedicinebusinessInterleukin 6Journal of Crohn's and Colitis
researchProduct

P017 C86/CD16 macrophages accumulate in the mucosa of B3 patients and could mediate EMT in Crohn’s disease

2020

Abstract Background Macrophages contribute to fibrosis through the release of different mediators and the pattern of secretion may vary according to their phenotype. Methods The aim of the present study is to analyse the pattern of expression of macrophages, of EMT-related genes and cytokines in surgical resections from Crohn’s disease (CD, n = 43) patients which were categorised according to Montreal classification (B2 or B3); unaffected mucosa of patients with ileocecal cancer was used as control (n = 20). mRNA was isolated from intestinal samples and the expression of macrophage, EMT markers and cytokines were analysed by RT-PCR. PBMCS were isolated from healthy donors and treated during…

Crohn's diseasebiologyU937 cellbusiness.industrymedicine.medical_treatmentGastroenterologyCancerMucous membraneVimentinGeneral Medicinemedicine.diseaseCytokinemedicine.anatomical_structureFibrosismedicinebiology.proteinCancer researchbusinessInterleukin 4Journal of Crohn's and Colitis
researchProduct

P051 Macrophages as a source of Notch Ligands in Crohn’s disease: implications in fibrosis

2021

Abstract Background Fibrosis constitute the main complications associated to Crohn’s disease (CD). Notch signalling has been implicated in lung, kidney, liver and cardiac fibrosis. Macrophages contribute to fibrosis through the release of different mediators and the pattern of secretion may vary according to their microenvironment. The aim of the present study is to analyze the role of Notch ligands derived from macrophages in the complications of CD. Methods We have analyzed: the mRNA expression of cytokines and Notch ligands in CD patients with fistulizing and stenting pattern, the mRNA and protein expression of macrophage markers and Notch ligands in macrophages treated with the main cyt…

Crohn's diseasebiologybusiness.industrymedicine.medical_treatmentGastroenterologyVimentinGeneral Medicinemedicine.diseaseInterleukin 10CytokineFibrosismedicinebiology.proteinCancer researchSignal transductionInterleukin 6businessInterleukin 4Journal of Crohn's and Colitis
researchProduct